Jean Francois Formela - Jun 9, 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role: Director
Signature: /s/ Ommer Chohan, as Attorney-in-Fact for Jean-Francois Formela
Stock symbol: IKNA
Transactions as of: Jun 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/13/2022, 06:08 PM
Previous filing: Dec 23, 2021
Next filing: Jun 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKNA	Stock Option (Right to Buy)	Award	$0	+13.4K		$0.00	13.4K	Jun 9, 2022	Common Stock	13.4K	$4.85	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the Reporting Person, a director of the Issuer, resigns from the Board or otherwise ceases to service as a director.
F2	The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Content

This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the Reporting Person, a director of the Issuer, resigns from the Board or otherwise ceases to service as a director.

The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.